Loading
A phase 1/2 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM is a phase 1/2 interventional study registered as NCT07217119 by GlaxoSmithKline, with 25 participants enrolled, started 2019-11-26 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Feladilimab. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
25 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication
Source95% CI 13.7 to 78.8; Figures from the ClinicalTrials.gov results section (first posted 2026-06-25), not from a publication · 95% CI 18.7 to 81.3 · 95% CI 22.3 to 95.7
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs)primary | 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab | 9 | 1 participants | - | - | link |
| 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab | 10 | 1 participants | ||||
| 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab | 6 | 0 participants | ||||
| DE Phase: Overall Response Rate (ORR) | 1.9 mg/kg Belantamab Mafodotin + 8 mg Feladilimab | 9 | 44% | - | - | link |
| 2.5 mg/kg Belantamab Mafodotin + 8 mg Feladilimab | 10 | 50% | ||||
| 2.5 mg/kg Belantamab Mafodotin + 24 mg Feladilimab | 6 | 67% |
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Feladilimab, Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, Relapsed or refractory multiple myeloma, Multiple myeloma, Antibody-drug conjugate (ADC).
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.